It's diagnostics, stupid

Cell. 2010 Apr 2;141(1):13-7. doi: 10.1016/j.cell.2010.03.018.

Abstract

To stem the spiraling cost of cancer treatment, a concerted effort is urgently needed to develop molecular diagnostics to better identify the patients that respond to expensive targeted therapies. Opportunities and obstacles in the development of such drug response biomarkers are discussed here.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Pharmacological / analysis*
  • Delivery of Health Care / economics
  • Humans
  • Neoplasms / diagnosis*
  • Neoplasms / drug therapy
  • Neoplasms / economics
  • Pathology, Molecular

Substances

  • Biomarkers, Pharmacological